Originally Aired: December 17, 2021
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

Optimizing the downstream process for adeno-associated virus (AAV) production with consistent quality depends on the ability to characterize critical quality attributes affecting the final product’s potency, purity, and safety.

As the gene therapy field continues to push products through the clinical pipeline, an increasing need for efficient analytical tools has become evident. In addition, the regulatory space has expanded in parallel to the use of AAV, driving the demand for simple and efficient assays to demonstrate product quality and safety. Analytical methods are needed for raw material testing, in-process control, and demonstrating the quality of the viral vector batch.

Join us for this GEN webinar, where our expert panelists will take you through the downstream process of AAV purification and the characterization steps associated with process development and their application in manufacturing lot release testing. In addition, you will learn more about process analytics and gain more knowledge on the tools which can help simplify the characterization steps of your AAV production process.

 

A live Q&A session followed the presentations, offering a chance to pose questions to our expert panelists.

Chantelle Gaskin
Chantelle Gaskin
Field Applications Specialist
Thermo Fisher Scientific
Ilaria Scarfone, PhD
Ilaria Scarfone, PhD
Field Applications Specialist
Thermo Fisher Scientific
Ken Cook, PhD
Ken Cook, PhD
EU manager BioPharma Experts Group
Thermo Fisher Scientific

Produced with support from:

Thermo Fisher Scientific logo